Amerikanische Gesellschaft für Hirudotherapie

Thrombosis during off pump LVAD placement in a patient with heparin induced thrombocytopenia using bivalirudin

Case report published in Journal of cardiothoracic surgery (2013)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportKlinische StudienArzneimittelentwicklungAwad H et al. · Journal of cardiothoracic surgery, 2013

Abstract

Here we present our attempt at off pump HeartMate II left ventricular assist device (LVAD) implantation using the anticoagulant bivalirudin in a patient with heparin induced thrombocytopenia, which resulted in thrombosis within the LVAD device. This required that our procedure be converted to on pump, and a new HeartMate II LVAD device to be implanted. In our view, this thrombotic event may have been caused by a number of factors that include bivalirudin's (1) short half-life of about 20 minutes, (2) decreased activity with blood stasis, (3) inability to prevent clot propagation, and (4) uncertainty with real-time monitoring of therapeutic levels. To prevent future thrombotic events, it may be beneficial to immediately deair the LVAD device prior to the coring of the left ventricle during off pump LVAD placement. In addition, a solution other than blood may be used for priming. If blood is used for priming of the LVAD device, the duration of blood stasis should not exceed 20 minutes when bivalirudin is being used for anticoagulation. Furthermore, this case emphasizes the importance of having a backup LVAD device available and ready to use during surgical procedures.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAgedAnticoagulantsAntithrombinsBlood CoagulationFemaleHeart VentriclesHeart-Assist DevicesHeparinHirudinsHumansPeptide FragmentsRecombinant Proteins

Zusammenfassung

Here we present our attempt at off pump HeartMate II left ventricular assist device (LVAD) implantation using the anticoagulant bivalirudin in a patient with heparin induced thrombocytopenia, which resulted in thrombosis within the LVAD device.

Warum dies für die Hirudotherapie relevant ist

This case report describes a patient with heparin-induced thrombocytopenia who underwent off-pump HeartMate II LVAD implantation using bivalirudin for anticoagulation, resulting in intra-device thrombosis that required conversion to on-pump surgery and device replacement. The authors attribute the failure to bivalirudin's short half-life (~20 minutes), decreased activity during blood stasis, limited ability to prevent clot propagation, and monitoring challenges, and offer procedural recommendations for future surgeries. The abstract does not mention hirudin, leeches, leech therapy, or the leech secretome; it discusses bivalirudin solely as an anticoagulant used in cardiac surgery. There is no defensible connection to hirudotherapy or ASH's domain based on the abstract alone.

Zitation

Thrombosis during off pump LVAD placement in a patient with heparin induced thrombocytopenia using bivalirudin

Awad H et al. · Journal of cardiothoracic surgery, 2013

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Clinical EvidenceClinical ApplicationsDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsBivalirudinHemostasisOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.